$0.65 -0.0 -0.0%
Last Trade - 26/02/21
| Market Cap | £15.5m |
| Enterprise Value | £19.1m |
| Revenue | £47.9m |
| Position in Universe | 5961st / 6715 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 177.4 | 166.9 | 132.5 | 102.2 | 88.1 | 79.7 | -14.8% | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
MusclePharm Corporation is a performance lifestyle company. The Company develops, manufactures, markets and distributes branded nutritional supplements. The Company offers a range of powders, capsules, tablets and gels. The Company's portfolio of brands targets various types of fitness enthusiasts, including professional, combat sport, weight training, bodybuilding, running, basketball, soccer, cross fit, golf, tennis, volleyball and other active lifestyle activities. The MusclePharm Sport Series includes supplements that cover the needs of athletes, including their workout needs. MusclePharm Hybrid Series products include Assault, Amino1 and Combat Protein Powder. FitMiss products are designed and formulated for the active woman's lifestyle utilizing ingredients that cover the range of busy women's needs, including weight loss, multi-vitamins, protein shakes, detox, skin care and pre-workout energy mixes. MusclePharm Core products include BCAA 3:1:2, CLA Core and Fish Oil.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | August 4, 2006 |
| Public Since | June 26, 2006 |
| No. of Shareholders: | n/a |
| No. of Employees: | 45 |
| Sector | Consumer Defensives |
| Industry | Food & Tobacco |
| Index | |
| Exchange | Pink Sheets on Nasdaq |
| Shares in Issue | 33,130,039 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 4400 W Vanowen St, BURBANK, 91505-1134, United States |
| Web | https://musclepharm.com/ |
| Phone | +1 303 3966100 |
| Contact | () |
| Auditors | EKS&H LLLP |
As of 26/02/21, shares in MusclePharm are trading at $0.65, giving the company a market capitalisation of £15.5m. This share price information is delayed by 15 minutes.
Shares in MusclePharm are currently trading at $0.65 and the price has moved by 0.364k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the MusclePharm price has moved by 0.254k% over the past year.
Of the analysts with advisory recommendations for MusclePharm, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for MusclePharm is Buy. You can view the full broker recommendation list by unlocking its StockReport.
MusclePharm is scheduled to issue upcoming financial results on the following dates:
MusclePharm does not currently pay a dividend.
MusclePharm does not currently pay a dividend.
MusclePharm does not currently pay a dividend.
To buy shares in MusclePharm you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in MusclePharm are currently trading at $0.65, giving the company a market capitalisation of £15.5m.
Here are the trading details for MusclePharm:
Based on an overall assessment of its quality, value and momentum, MusclePharm is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in MusclePharm are currently priced at $0.65. At that level they are trading at 0.154% discount to the analyst consensus target price of 0.00.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MusclePharm. Over the past six months, the relative strength of its shares against the market has been 0.323k%. At the current price of $0.65, shares in MusclePharm are trading at 0.134k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for MusclePharm.
MusclePharm's management team is headed by:
Here are the top five shareholders of MusclePharm based on the size of their shareholding:
